Appia Bio
Monica Jenkins has extensive experience in human resources, starting in 2006 as a Consultant at PDL BioPharma. Monica later worked as an HR Business Partner at the Bill and Melinda Gates Foundation, where they collaborated with leaders and employees on innovative people strategies. From 2009 to 2016, Monica served as the Senior Director of Human Resources at Medivation, building the HR function and managing C-suite clients. Monica then joined Pfizer as a Senior Director of Human Resources, overseeing the Commercial and IT organizations. Monica also worked as a Senior HR Consultant at Christine Mathews Consulting, Inc. and as a Senior Director of Human Resources at Astellas Gene Therapies. Most recently, they held the position of Senior Director of HR at Mirati Therapeutics. Monica currently works at Appia Bio as the Head of Human Resources, contributing their expertise as a consultant.
Monica Jenkins holds a Bachelor of Science in Psychology from Santa Clara University. In addition to their degree, they have obtained various certifications and completed professional development courses. These include certifications such as "Executive Presence on Video Conference Calls" and "Managing Your Career as an Introvert" from LinkedIn, as well as the "Certified Dare to Lead™ Facilitator" from the Certified Dare to Lead™ Facilitator institution. Monica has also completed the "Executive & Transitional Coach" program at the Hudson Institute of Coaching and the "Cambria Internal Coaching" program at Cambria Counsulting. Furthermore, Monica is an Associate Certified Coach (ACC) certified by the International Coaching Federation and the INTERNATIONAL COACH FEDERATION SAN FRANCISCO SF COACHES. Lastly, they have a DDI certification, although the details of the institution and the obtained month and year are not provided.
This person is not in any teams
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).